Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1008 results about "Kinase" patented technology

In biochemistry, a kinase is an enzyme that catalyzes the transfer of phosphate groups from high-energy, phosphate-donating molecules to specific substrates. This process is known as phosphorylation, where the substrate gains a phosphate group and the high-energy ATP molecule donates a phosphate group. This transesterification produces a phosphorylated substrate and ADP. Conversely, it is referred to as dephosphorylation when the phosphorylated substrate donates a phosphate group and ADP gains a phosphate group (producing a dephosphorylated substrate and the high energy molecule of ATP). These two processes, phosphorylation and dephosphorylation, occur four times during glycolysis. Kinases are part of the larger family of phosphotransferases. Kinases should not be confused with phosphorylases, which catalyze the addition of inorganic phosphate groups to an acceptor, nor with phosphatases, which remove phosphate groups. The phosphorylation state of a molecule, whether it be a protein, lipid, or carbohydrate, can affect its activity, reactivity, and its ability to bind other molecules. Therefore, kinases are critical in metabolism, cell signalling, protein regulation, cellular transport, secretory processes, and many other cellular pathways, which makes them very important to human physiology.

Bioengineering bacteria for full fermentation of stevioside and application of bioengineering bacteria

The invention belongs to the technical field of biosynthesis, and particularly relates to an engineering bacterium for preparing stevioside through de novo fermentation as well as a preparation method and application of the engineering bacterium. According to the invention, mevalonate kinase in the MVA pathway is mutated and optimized. The method comprises the following steps: carrying out point mutation on mevalonate kinase MvK of a wild type source, constructing a stevioside synthesis route in an escherichia coli host, and comparing the influence of MvK mutation on the yield of stevioside, so as to determine a Q160L mutant, and applying the Q160L mutant to the stevioside production route to realize efficient production of stevioside.
Owner:SICHUAN INGIA BIOSYNTHETIC CO LTD

Valine production strain as well as construction method and application thereof

The invention provides a valine production strain and a construction method and application thereof, a designed acetohydroxy acid synthase mutant is that the 88th basic group of an ilvB gene is changed from a to c, the 382nd basic group is changed from a to g, the 413th basic group is changed from c to t, the gene sequence of a designed artificial operon comprises a promoter, an ilvB (A138V) gene or ilvB (Q30K, S128G, A138V) gene of coding mutated acetohydroxy acid synthase, and an ilvN (G20D, I21D, I21D, I21D, I21D, I21D, I21D, I21D) gene. I22F) gene, a pyk gene for coding pyruvate kinase, and a terminator; by designing a specific acetohydroxyacid synthase mutant and related biological materials and artificial operon, the strain constructed by directional modification of the strain by using a pK18mobsacB system gene editing technology based on allele exchange has the advantages of good genetic stability, high fermentation yield and the like, and valine can be stably produced.
Owner:TIANJIN HERUN BIOTECHNOLOGY CO LTD

Bifunctional degradation products of hematopoietic precursor kinases and their therapeutic use

The present disclosure provides bifunctional compounds as HPK1 degraders via the ubiquitin proteosome pathway and methods for treating diseases modulated by HPK1. The present invention provides novel bifunctional compounds for proteolytically degrading hematopoietic progenitor kinase (HPK1) and methods for treating diseases modulated by HPK1. HPK1 can be targeted for degradation, thereby providing therapeutic opportunities in enhancing anti-tumor immunity and increasing responses to checkpoint receptor blockade.
Owner:NURIX THERAPEUTICS INC +1

Recombinant escherichia coli with high yield of N-acetylneuraminic acid and application of recombinant escherichia coli

PendingCN121975706Ameet supply needsSufficient supplyBacteriaMicroorganism based processesEscherichia coliPhosphorylation
The invention discloses recombinant escherichia coli with high yield of N-acetylneuraminic acid and application of the recombinant escherichia coli, and relates to the technical field of biological genetic engineering. The invention relates to a recombinant escherichia coli, which is characterized in that the escherichia coli is taken as a host, and free expression of an N-acetylmannosamine epimerase gene yihS from Streptomyces xiamenensis or an N-acetylmannosamine epimerase gene ce3 from Bacteroides polymorpha and an exogenous N-acetylneuraminic acid lyase gene nano A is carried out; and carrying out recombinant expression on N-acetyl hexosamine 1-kinase nahK, a UDP-N-acetyl glucosamine pyrophosphorylase gene glmU and a UDP-N-acetyl glucosamine-2-epimerase gene neuC in the other synthetic route of the ManNAc. According to the recombinant escherichia coli with high yield of N-acetylneuraminic acid, the yield of N-acetylneuraminic acid can reach 23.08 g / L under a shake flask fermentation condition; a two-stage batch feeding strategy is adopted, the yield of N-acetylneuraminic acid in a 5L fermentation tank reaches 71.25 g / L, the molar conversion rate of GlcNAc reaches up to 57.60%, and the method has the potential of industrial application.
Owner:JIANGNAN UNIV

Method for enhancing synthesis of myo-inositol as well as engineering bacteria and application thereof

PendingCN121852304ABacteriaHydrolasesInositol synthesisGlycerol kinase
The invention belongs to the field of metabolic engineering, and discloses a genetically engineered bacterium for producing myo-inositol as well as a construction method and application of the genetically engineered bacterium. The genetically engineered bacterium takes escherichia coli as an original strain, and is obtained by performing the following gene editing on a genome of the escherichia coli: non-expressed lactose operon repressor protein, glucose phosphate dehydrogenase, acetokinase, glucose phosphate isomerase and glycerol repressor protein; and overexpressing inositol-1-phosphate synthase, inositol monophosphate, glucokinase, glucose permease and glycerol kinase. Compared with the prior art, the genetically engineered bacterium disclosed by the invention has remarkable advantages in the aspects of key enzyme expression rate, metabolism specificity, fermentation period and the like, and an efficient, stable, economical and feasible solution is provided for industrial production of myo-inositol.
Owner:TIANJIN UNIV OF SCI & TECH

Tolebrutinib for multiple sclerosis

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase ("BTK") inhibitors, for treatment of patients with multiple sclerosis (MS).
Owner:PRINCIPIA BIOPHARMA INC

Application of engineered citrobacter freundii in fermentation synthesis of stabilizers

The invention discloses an application of engineered citrobacter freundii in fermentation synthesis of a stable body. The engineered citrobacter freundii is citrobacter freundii overexpressing a polyphosphate kinase gene Ppk1. The stable body prepared by fermenting the engineered citrobacter freundii is rich in polyphosphates and polyamines, particularly, the content of the polyamines can be up to 21wt%, the polyphosphates in the stable body can store the polyamines in an ionic bond combination mode, the combined polyamines are insoluble in water, a natural anion coating is generated, and the stability of the stable body is improved. And the sustained-release tablet is not easily taken by intestinal epithelial cells, so that the sustained-release tablet has a certain sustained-release effect. The medicine prepared by taking the compound as a main active ingredient shows a remarkable curative effect in ulcerative colitis treatment, has the comprehensive effects of reducing oxidative stress, enhancing the anti-inflammatory ability of a body and regulating immunity, is suitable for patients of all ages, and has outstanding application value and market prospect.
Owner:NANJING UNIV

Construction method of escherichia coli mutant for producing succinic acid by fermentation of synthetic culture medium

The invention discloses a construction method of an escherichia coli mutant for producing succinic acid by fermentation of a synthetic medium. The method comprises the following steps: firstly, knocking out a lactic dehydrogenase gene ldhA, a pyruvate formate lyase gene pflB, a ptsG gene responsible for encoding a phosphotransferase system EIIBC protein, an ethanol dehydrogenase gene adhE, an acetokinase-phosphate transacetylase gene ackA-pta, and a ptsG gene responsible for encoding a phosphotransferase system EIIBC protein in escherichia coli; a phosphoenolpyruvate carboxykinase gene pck from bacillus subtilis is integrated at an SS9 safety site of a strain to obtain escherichia coli ESC6 with high succinic acid yield; and mutating one or more loci in one or more genes of a glucose-transcriptional inhibition factor gene mlc, a nitrate response regulatory factor gene narL and a cyclic adenylate receptor protein gene crp to obtain the escherichia coli mutant capable of producing succinic acid by fermentation of a synthetic culture medium, wherein the one or more loci in one or more genes of the glucose-transcriptional inhibition factor gene mlc, the nitrate response regulatory factor gene narL and the cyclic adenylate receptor protein gene crp are mutated. The strain can be fermented in a synthetic medium to produce succinic acid, so that the fermentation cost is greatly reduced, and the strain has a very wide application prospect.
Owner:DALIAN UNIV OF TECH

Ergothioneine-producing recombinant engineering bacterium as well as construction method and application thereof

The invention discloses an ergothioneine-producing recombinant engineering bacterium as well as a construction method and application thereof, and belongs to the technical field of gene recombination fermentation. The method comprises the following steps: by taking escherichia coli as a starting bacterium, carrying out recombinant expression on a histidine trimethyl inner salt cysteine sulfoxide synthetase egt1 gene, an L-histidine methyltransferase egtD gene, a histidine trimethyl inner salt cysteine sulfoxide lyase egt2 gene, a methionine adenosine transferase metK gene, an adenylate kinase adK gene and an adenine phosphoribose transferase apt gene; on this basis, supply of precursor substances including histidine, cysteine and methionine is further improved through metabolic transformation, the yield of the finally obtained recombinant engineering bacterium for producing ergothioneine reaches 2.54 g / L after 48 h of shake-flask culture, the yield of a 5L fermentation tank reaches 18 g / L after further enlarged culture, the yield of ergothioneine is guaranteed while energy consumption and cost are reduced, and the method is suitable for industrial production. The method is suitable for practical popularization.
Owner:SHANGHAI RECOM BIOTECHNOLOGY CO LTD

Aspartate kinase and application thereof

The invention relates to aspartate kinase for relieving feedback inhibition of L-threonine and application of aspartate kinase, and belongs to the field of enzyme engineering and metabolic engineering. The mutant is obtained by carrying out E253K and / or K507E mutation on the basis of wild type aspartate kinase as shown in SEQ ID NO.1, the enzyme activity of the mutant is not obviously changed under the condition that the concentration of L-threonine is 0-12 mmol / L, and the feedback inhibition effect of L-threonine on the mutant is relieved. The method can be widely applied to synthesis of essential amino acids including L-threonine, L-tryptophan, L-isoleucine, L-lysine, L-leucine, L-valine, L-methionine, L-phenylalanine and the like.
Owner:TIANJIN UNIV OF SCI & TECH

Tyrosine kinase inhibitor and activin type 2 receptor antagonist combination therapy for treating pulmonary arterial hypertension (PAH)

Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), comprising administering to a subject in need thereof: •a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof; and•a therapeutically effective amount of a dimeric fusion protein comprising: •the extracellular domain of the activin type 2A (ACTR IIA) or the activin type 2B receptor (ACTR IIB); and the Fc domain of human immunoglobulin G1 (IgG1). In some embodiments, the tyrosine kinase inhibitor is Seralutinib or a pharmaceutically acceptable salt thereof and the fusion protein is Sotatercept.
Owner:GB002 INC

Modified aureobasidium pullulans strain based on reduction of malic acid pathway consumption and application thereof

PendingCN121801715AFungiMicroorganism based processesPullulanCarbon metabolism
The invention discloses a modified aureobasidium pullulans strain based on reduction of malic acid pathway consumption and application of the modified aureobasidium pullulans strain. Gene for coding NADPH dependent malic enzyme and phosphoenolpyruvate carboxykinase in an aureobasidium pullulans genome is directionally knocked out. The transformation blocks a key consumption branch for synthesis and accumulation of the cytoplasmic malic acid, and effectively guides a central carbon metabolic flow to be more efficiently guided to a target product. Experimental results show that the polymalic acid yield and the saccharic acid conversion rate of the double-knockout engineering strain D3N5-delta3617 / deltapepck in fermentation are remarkably improved compared with those of an original strain, and the biomass is also increased. The invention provides a high-performance strain with important application value for industrial efficient fermentation production of polymalic acid.
Owner:SOUTHWEST UNIV

Phosphonate-drug conjugates

This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and / or inner ear. Methods of treating diseases or disorders of the middle ear and / or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided.
Owner:UNIV OF SOUTHERN CALIFORNIA +1

Covalent polypeptide inhibitors, conjugates, kits, pharmaceutical compositions, and uses targeting protein kinase a

PendingCN122628143AProtein targetAcyl group
The application discloses a covalent polypeptide inhibitor targeting protein kinase A, a conjugate, a kit, a pharmaceutical composition and application. The general formula of the covalent polypeptide inhibitor is Z1-Seq-Z2; wherein Seq is an amino acid sequence; the C-terminal of Seq comprises a pseudo-substrate recognition motif recognized by protein kinase A, a non-natural amino acid with a covalent reaction group, and can be covalently crosslinked with a Cys200 residue on a catalytic subunit of protein kinase A; Z1 is selected from hydrogen, an acyl group, a fluorescent group, biotin, an isotopic tag or a biological ortho-reaction group; and Z2 is selected from a hydroxyl group, an amino group, a cell-penetrating peptide or a stabilization modification group. The covalent polypeptide inhibitor can strongly and irreversibly inhibit PKA activity, and can be used as an active probe to specifically label active PKA in a complex biological sample, and is used for biological research and drug development.
Owner:PEKING UNIV +1

Diagnostic test

The present invention relates to a non-invasive test for the detection of deep endometriosis. Particularly, although not exclusively, aspects of the present invention relate to one or more glycolysis-associated biomarkers (e.g., phosphoglycerate mutase 1 (PGAM1), Enolase-1 (ENO1), phosphofructokinase-1 (PFKP) and / or Hexokinase) and / or cytokines associated with aerobic glycolysis (e.g., IL-6 and / or TGF-β) which can be used to determine the likelihood of a subject having deep endometriosis based on a sample obtained from the subject.
Owner:UNIVERSITY OF HULL

Preparation method of novel composite carbon source

InactiveCN121087071ABacteriaTransferasesBiotechnologyPlasmid dna
The invention discloses a preparation method of a novel composite carbon source. The preparation method comprises the following steps: S1, preparing a solution; s2, preparing a culture medium; s3, extracting a genome; s4, extraction of plasmid DNA (deoxyribonucleic acid); s5, preparation of agarose gel electrophoresis; s6, constructing a linearized vector plasmid; s7, preparing an electrotransfection competent cell; and S8, electric conversion treatment. According to the preparation method of the novel composite carbon source, pfkA and pfkB can be respectively, independently and simultaneously knocked out when the carbon source is prepared by utilizing a gene editing technology, the consumption of a glucosamine precursor 6-fructose phosphate in an EMP pathway can be reduced, more glucose is used for synthesizing a target product, and by optimizing the preparation process of the composite carbon source, the yield of the target product is improved. The shake-flask fermentation yield of the glucosamine can be obviously improved, the conversion rate of the composite carbon source is also improved, and cell growth and synthesis of the target product glucosamine can be reasonably balanced, so that the yield of the glucosamine is improved.
Owner:GUANGDONG JIAYUAN ECOLOGICAL ENVIRONMENT CO LTD

Dual-target drug or pharmaceutical composition for preventing, alleviating, or treating cancer, treatment method, and use

The present application relates to a drug or pharmaceutical composition for preventing, alleviating, or treating cancer and a use thereof, as well as a method for preventing, alleviating, or treating cancer. The drug or pharmaceutical composition of the present application is capable of interfering with ataxia-telangiectasia mutated and Rad3-related kinase (ATR) and mammalian target of rapamycin (mTOR) activity, causing inactivation or reduced activity of ATR and mTOR. The present application provides a novel dual-target strategy for the treatment of cancer.
Owner:LITTDD MEDICINES LTD

Use of a bruton's tyrosine kinase inhibitor

The application provides use of a compound A or a pharmaceutically acceptable salt thereof as a Bruton's tyrosine kinase (BTK) inhibitor in preparation of a drug for treating a BTK-related tumor disease. In vitro and in vivo test results show that the compound A has good inhibitory activity on BTK kinase, good inhibitory activity on human B-cell lymphoma cells with high BTK expression, and good in vivo anti-tumor activity. In addition, the compound A has good pharmacokinetic properties and metabolic stability, and can be used for developing a drug preparation for treating a BTK-related tumor disease, and has important clinical application value.
Owner:SHANGHAI RUNSHI MEDICAL TECH CO LTD +1

A PAK4 kinase inhibitor, its preparation method and uses

This invention discloses a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, or solvate thereof. Experimental results show that the compound provided by this invention exhibits high inhibitory activity against PAK4 kinase and PAK I / II selectivity, good liver microsomal stability, and rat PK pharmacokinetic properties, especially with low hERG cardiotoxicity risk, representing a significant improvement over prior art compounds.
Owner:CHENGDU HYPERWAY PHARM CO LTD +1

Recombinant bacterium for improving yield of alpha-bisabolol as well as preparation method and application of recombinant bacterium

The invention discloses a recombinant bacterium capable of increasing the yield of alpha-bisabolol as well as a preparation method and application of the recombinant bacterium, and belongs to the technical field of microorganisms. The invention aims to improve the yield of alpha-bisabolol and enhance the tolerance of a host to an organic solvent. The invention provides a recombinant bacterium for improving the yield of alpha-bisabolol. Escherichia coli is used as a starting strain; the method comprises the following steps of: overexpressing an acetyl CoA acyltransferase / HMG-CoA reductase mvaE gene, an HMG-CoA synthetase mvaS gene, a 2-methyl citrate dehydratase prpD gene, a mevalonate kinase ERG12 gene, a mevalonate 5-phosphate kinase ERG8 gene, a mevalonate 5-diphosphate decarboxylase ERG19 gene and an isopentenyl diphosphate isomerase idi gene, so as to obtain a recombinant vector; the gene is obtained from an alpha-bisabolol synthase gene of artichoke, a farnesyl diphosphate synthase ispA gene and an alpha-bisabolol synthase CcBOS gene of artichoke. The industrial process of synthesizing alpha-bisabolol by a biological method is promoted.
Owner:QINGDAO INST OF BIOENERGY & BIOPROCESS TECH CHINESE ACADEMY OF SCI

Sulfonyl-triazoles useful as covalent activators of the glycolytic enzyme PFKL for t cell activation

PCT designated stageWO2026006838A1Organic chemistrySulfur/selenium/tellurium active ingredientsAcyl groupGlycolytic enzymes
A family of sulfonyl-azole compounds are described which include small molecule activators of phosphofructokinase-1, liver isoform (PFKL). The small molecule activators selectively form covalent adducts with PFKL, including particularly lysine 677 of the human PFKL. Also provided are methods for using the small molecule activators to activate PFKL, e.g., to provide increased glycolysis and / or T cell activation, to treat cancers and / or tumors, and / or to enhance fructose-1,6-bisphosphate (FBP) content in cells.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Use of chiral tetrahydropyrazolo[1,5-a]pyrimidine derivatives for the preparation of antitumor drugs for the treatment of HER2-positive colorectal cancer

The application discloses application of a chiral tetrahydropyrazolo[1,5-a]pyrimidine derivative in preparation of an antitumor drug for treating HER2 positive colorectal cancer. Through in vitro and in vivo experiments, it is confirmed that the compound has a significant inhibitory effect on proliferation and migration of HER2 positive colorectal cancer cells, and shows antitumor activity. The application provides a new idea for developing a novel tyrosine kinase inhibitor for treating HER2 positive colorectal cancer in clinic.
Owner:THE SECOND HOSPITAL OF DALIAN MEDICAL UNIV

Cascade biological catalysis-based pyridoxal phosphate synthesis method capable of autonomously supplying ATP (adenosine triphosphate)

The invention relates to a pyridoxal phosphate (PLP) synthesis method based on cascade biological catalysis and capable of realizing ATP autonomous regeneration. The method comprises the following steps: constructing engineering bacteria for co-expressing pyridoxal phosphate kinase (PdxK) and polyphosphate kinase (PPK) to prepare a whole-cell catalyst or a crude enzyme solution; under the condition that ATP does not need to be exogenously added, pyridoxal, ADP and polyphosphate serve as substrates, cascade reaction is carried out under the action of a catalyst, ATP is regenerated in situ, and PLP synthesis is driven. A wild enzyme system is adopted, and the yield of PLP exceeds 95% within 4 hours of reaction; after PdxK mutation optimization, the reaction time is shortened to about 2 hours, and conversion can be completed. According to the invention, a polyphosphate-driven ATP regeneration system is coupled with PLP biosynthesis, so that the cofactor cost is remarkably reduced, a feasible technical path is provided for industrial biological manufacturing of PLP, and the application of polyphosphate in cyclic regeneration of cofactors is expanded.
Owner:ZHEJIANG NORMAL UNIV XINGZHI COLLEGE

Fused tricyclic substituted isoxazolidinyl urea derivative, pharmaceutical composition and application thereof

The invention relates to the technical field of medicines, in particular to fused tricyclic substituted isoxazolidinyl urea derivatives, pharmaceutically acceptable salts, stereoisomers, pharmaceutical compositions and application thereof. The structure of the fused tricyclic substituted isoxazolidinyl urea derivative is as shown in a formula (I). The fused tricyclic substituted isoxazolidinyl urea derivative disclosed by the invention has obvious TrkA kinase and cell inhibition activity and selective inhibition activity.
Owner:SHANGHAI HAIYAN PHARMA TECH +2